LarryDCripeMD
Oncology • Indianapolis, INAssociate Professor, Medicine, Indiana University School of Medicine
Dr. Cripe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1030 W Michigan St
Indianapolis, IN 46202Phone+1 317-944-0920Fax+1 317-944-2181- Is this information wrong?
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1987 - 1990
Rush University Medical CenterResidency, Internal Medicine, 1984 - 1987
Rush Medical College of Rush University Medical CenterClass of 1984
Certifications & Licensure
IN State Medical License 1995 - 2025
NC State Medical License 1987 - 1998
MI State Medical License 1993 - 1997
IL State Medical License 1985 - 1987- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Indianapolis Monthly Castle Connolly, 2013
- Top MD Consumers Checkbook
Clinical Trials
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Start of enrollment: 2002 Sep 17
- Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes Start of enrollment: 2006 Sep 01
- Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T Gildea, Samuel Haddox, Tak Lee, H Moses Murdock, Caroline Sheridan, Alexis...> ;Blood Cancer Journal. 2023 Jul 6
- 1 citationsObesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.James M Foran, Zhuoxin Sun, Catherine Lai, Hugo F Fernandez, Larry D Cripe, Rhett P Ketterling, Janis Racevskis, Selina M Luger, Elisabeth Paietta, Hillard M Lazarus, ...> ;Cancer. 2023 Aug 15
- We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death.Ann H Cottingham, Layla B Baker, Mary Lynn Hoffmann, Caroline E Martin, Larry D Cripe> ;Leukemia Research. 2023 Jan 1
- Join now to see all
Press Mentions
Chuckstrong Tailgate Gala Raises More Than $2 Million, Marking a Decade of Dedication to IU Cancer ResearchAugust 5th, 2022- Cancer Interrupted Campus ‘Dad’s Weekend’ for Devoted FatherOctober 3rd, 2021
After Cancer Treatment, Complementary Care CalmsOctober 8th, 2016- Join now to see all
Grant Support
- Single-Center Phase I Study To Determine The Optimal Biologic Dose Of Cc-401National Center For Research Resources2007–2008
- Zosuquidar Trihydrochloride During Conventional Induction And Post-RemissionNational Center For Research Resources2006
- Clinical Research OfficeNational Cancer Institute2004
- Ly335979, Daunorubicin, Cytarabine In Myelogenous LeukemNational Center For Research Resources2000–2002
Professional Memberships
- Member
Hospital Affiliations
Eskenazi HealthIndianapolis, Indiana
Richard L. Roudebush Veterans Affairs Medical CenterIndianapolis, Indiana
Indiana University Health University HospitalIndianapolis, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
